Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054938 · ClinicalTrials.gov registry record · Phase 2
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00054938 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 150 participants.
The verdict
NCT00054938, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to find the best way to prevent heart disease and stroke in people with lupus (systemic lupus erythematosis, or SLE). The study will evaluate the effectiveness of medication and a phone-based education program in controlling four risk factors for heart disease: smoking, obesity, high blood pressure, and inactivity. The study will also test the safety of commonly used heart medications in people with lupus.
Interventions
- DRUG aspirin
- DRUG pravastatin
- DRUG ramipril
- DRUG Vitamins: B6, B12, and folate
- BEHAVIORAL heart health educational program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054938
The ClinicalTrials.gov registry entry for NCT00054938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which aspirin is the first listed.
NCT00054938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054938 about?
NCT00054938 is a clinical study titled "Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)". The purpose of this study is to find the best way to prevent heart disease and stroke in people with lupus (systemic lupus erythematosis, or SLE). The study will evaluate the effectiveness of medication and a phone-based education program in controlling four risk factors for heart disease: smoking, ...
What is the current status of trial NCT00054938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-03. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00054938?
The interventions under investigation include: aspirin (DRUG), pravastatin (DRUG), ramipril (DRUG), Vitamins: B6, B12, and folate (DRUG), heart health educational program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00054938?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.